Background/Aims: Allgrove syndrome is a rare autosomal recessive disorder characterized by alacrima, achalasia, and adrenal insufficiency. It is caused by mutations of the AAAS gene located on chromosome 12q13 encoding the WD-repeat protein ALADIN. The c.1331+1G>A mutation is one of the most common mutations described in the literature and was identified in Tunisian and Algerian populations. Herein, we describe the clinical and genetic profile of two families from Libya in North Africa associated with Allgrove syndrome. Methods: Two unrelated families clinically diagnosed with Allgrove syndrome were evaluated for sequence variations in the AAAS gene. Blood samples were collected, and isolated DNA derived from the subjects was amplified. The entire sequence of the AAAS gene was analyzed by PCR-RFLP and direct sequencing. Results: Molecular analysis revealed the major homozygous mutation (c.1331+1G>A) in all patients. The presence of a major mutation in Tunisia, Algeria and, as discovered in this report, in Libya in patients with Allgrove syndrome suggests the existence of an ancestral mutation and a founder effect in North Africa. Conclusions: The findings allow for a fast genetic counseling in North African families with Allgrove syndrome. To the best of our knowledge, this is the first report of Allgrove syndrome in Libya.

Keywords:
AAAS gene, Allgrove syndrome, c.1331+1G>A mutation, Founder effect, North Africa
1.
Online Mendelian Inheritance in Man (OMIM), Center for Medical Genetics, Johns Hopkins University, and National Center for Biotechnology Information, US National Library of Medicine. Bethesda, Md. http://www.ncbi.nlm.nih.gov/omim.
2.
Allgrove J, Clayden GS, Grant DB, Macaulay JC: Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1978;1:1284-1286.
3.
Geffner ME, Lippe BM, Kaplan SA, Berquist WE, Bateman JB, Paterno VI, Seegan R: Selective ACTH insensitivity, achalasia, and alacrima: a multisystem disorder presenting in childhood. Pediatr Res 1983;17:532-536.
4.
Gazarian M, Cowell CT, Bonney M, Grigor WG: The ‘4A' syndrome: adrenocortical insufficiency associated with achalasia, alacrima, autonomic and other neurological abnormalities. Eur J Pediatr 1995;154:18-23.
5.
Tsao CY, Romshe CA, Lo WD, Wright FS, Sommer A: Familial adrenal insufficiency, achalasia, alacrima, peripheral neuropathy, microcephaly, normal plasma very long chain fatty acids, and normal muscle mitochondrial respiratory chain enzymes. J Child Neurol 1994;9:135-138.
6.
Cronshaw JM, Krutchinsky AN, Zhang W, Chait BT, Matunis MJ: Proteomic analysis of the mammalian nuclear pore complex. J Cell Biol 2002;158:915-927.
7.
Dreger M, Bengtsson L, Schoneberg T, Otto H, Hucho F: Nuclear envelope proteomics: novel integral membrane proteins of the inner nuclear membrane. Proc Natl Acad Sci USA 2001;98:11943-11948.
8.
Kind B, Koehler K, Lorenz M, Huebner A: The nuclear pore complex protein ALADIN is anchored via NDC1 but not via POM121 and GP210 in the nuclear envelope. Biochem Biophys Res Commun 2009;390:205-210.
9.
Krumbholz M, Koehler K, Huebner A: Cellular localization of 17 natural mutant variants of ALADIN protein in triple A syndrome - shedding light on an unexpected splice mutation. Biochem Cell Biol 2006;84:243-249.
10.
Dumic M, Barisic N, Rojnic-Putarek N, Kušec V, Stanimirović A, Koehler K, Huebner A: Two siblings with triple A syndrome and novel mutation presenting as hereditary polyneuropathy. Eur J Pediatr 2011;170:393-396.
11.
Tullio-Pelet A, Salomon R, Hadj-Rabia S, Mugnier C, de Laet MH, Chaouachi B, Bakiri F, Brottier P, Cattolico L, Penet C, Bégeot M, Naville D, Nicolino M, Chaussain JL, Weissenbach J, Munnich A, Lyonnet S: Mutant WD-repeat protein in triple-A syndrome. Nat Genet 2000;26:332-335.
12.
Lewin HA, Stewart-Haynes JA: A simple method for DNA extraction from leukocytes for use in PCR. Biotechniques 1992;13:522-524.
13.
Huebner A, Kaindl AM, Knobeloch KP, Petzold H, Mann P, Koehler K: The triple A syndrome is due to mutations in ALADIN, a novel member of the nuclear pore complex. Endocr Res 2004;30:891-899.
14.
Genin E, Tullio-Pelet A, Begeot F, Lyonnet S, Abel L: Estimating the age of rare disease mutations: the example of triple-A syndrome. J Med Genet 2004;41:445-449.
15.
Sandrini F, Farmakidis C, Kirschner LS, Wu SM, Tullio-Pelet A, Lyonnet S, Metzger DL, Bourdony CJ, Tiosano D, Chan WY, Stratakis CA: Spectrum of mutations of the AAAS gene in Allgrove syndrome: lack of mutations in six kindreds with isolated resistance to corticotropin. J Clin Endocrinol Metab 2001;86:5433-5437.
16.
Chang AJ, Kline MM, Currie Y, Perez MO, Hartiala J, Wijesuriya H, Buchanan TA, Watanabe RM, Allayee H: Allgrove syndrome in a Mexican American family is caused by an ancestral mutation derived from North Africa. Clin Genet 2008;73:385-387.
17.
Yassaee VR, Soltani Z, Ardakani BM: Mutation spectra of the AAAS gene in Iranian families with Allgrove syndrome. Arch Med Res 2011;42:163-168.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.